Since last year’s ovarian cancer awareness month there have been numerous advancements in treatment options for patients with ovarian cancer. Rubraca™ (rucaparib) was approved in December 2016, and Zejula™ (niraparib) received FDA approval in March 2017. Recently, Olaparib® was granted approval for a new tablet formulation and an expanded label that includes maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. These recent approvals are major steps forward in treating ovarian cancer; however, there is still room for improvement.
Since September is ovarian cancer awareness month, it seems like a fitting time to spread awareness of clinical trials that are currently recruiting patients as that will help maintain the momentum of therapeutic advancement for patients with ovarian cancer.
Platinum, Avastin and OLAparib in 1st Line (PAOLA-1)
This is a phase III Trial of the PARP inhibitor olaparib vs. placebo in patients with advanced stage IIIB – IV high grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer treated with standard first-line treatment of platinum-taxane chemotherapy and bevacizumab.
The primary purpose of this study is to evaluate the safety and efficacy of olaparib in patients receiving bevacizumab maintenance therapy.
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
This is a Phase III, open-label, international, multi-center efficacy and safety study of the PD-L1 inhibitor avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer and be candidates for platinum-based chemotherapy.
The primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance setting following frontline chemotherapy or in combination with carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by observation in this population of newly diagnosed patients with ovarian cancer.
Olaparib Treatment in Relapsed Germline BRCA Mutated Patients With Ovarian Cancer Patients (SOLO3)
This is a Phase III trial comparing olaparib vs. physician’s choice of single agent standard of care non-platinum based chemotherapy in patients with germline BRCA mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy. Patient should have received at least 2 prior lines of platinum based chemotherapy.
The primary purpose of the study is to assess the efficacy and safety of olaparib tablets by assessment of progression-free survival (PFS).
Trial on Trabectedin (ET-743) vs Clinician’s Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients (MITO-23)
This is an open-label, multi-center Phase III clinical trial trabectedin in patients with advanced invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer and a BRCA1/BRCA2 mutations or BRCAness phenotype vs. physician’s choice chemotherapy.
The primary purpose of this study is to evaluate the safety and efficacy of trabectidin in patients with advanced ovarian cancer, with a primary endpoint of overall survival.
Learn More about Clinical Trials for Patients with Ovarian Cancer by Visiting: ClinicalTrials.gov